Disclosure: We earn commissions on purchases made through our links. This never influences our scores. Editorial policy
Akkermansia muciniphila
Bottom line
In our scoring, Akkermansia muciniphila rates mixed evidence: the evidence is mixed for insulin sensitivity and metabolic markers. Our top-scored product is Akkermansia Probiotic (72/100), about $1.80 a day at a clinical dose of The human trial used ~10 billion pasteurized cells/day. Bottom line: promising but not settled, so manage expectations. This is our opinion, not medical advice; talk to your clinician before starting.
Akkermansia muciniphila is the "next-generation" probiotic that the GLP-1 era made famous, and for once the science behind the hype is genuinely interesting - it is just early.
- Evidence
- Mixed Evidence
- Category
- Probiotics & Gut Health
- Best form
- delayed-release capsule (survives stomach acid)
- Effective dose
- The human trial used ~10 billion pasteurized cells/day
- Lab tested
- 3 of 5 products
- Category
- Probiotics & Gut Health
- Best form
- delayed-release capsule (survives stomach acid)
- Effective dose
- The human trial used ~10 billion pasteurized cells/day
- Lab tested
- 3 of 5 products
Key takeaways
- →A genuinely interesting 'next-gen' probiotic: it secretes a protein that triggers GLP-1 release, the same hormone Ozempic-class drugs mimic - which is why it is marketed as natural GLP-1 support.
- →The evidence is early: one small human RCT (Depommier 2019) improved insulin sensitivity ~30%, but with the pasteurized form - while most products sell the live form, at ~100x lower doses than the study used.
- →Pendulum ($1.80/day) is our Top Pick - the patented, clinically studied strain and the only brand with its own human data. Codeage ($0.39/day) is the credible cheaper alternative at a matching cell count.
- →Ignore obscure brands claiming '30 billion' live Akkermansia - those counts are implausible for a strict anaerobe and we found no independent verification. Refrigerate whichever you choose.
What Is Akkermansia muciniphila?
Akkermansia muciniphila is the "next-generation" probiotic that the GLP-1 era made famous, and for once the science behind the hype is genuinely interesting - it is just early. This is a single gut bacterium that, in a proof-of-concept human trial, improved insulin sensitivity and nudged down body weight and cholesterol. It also happens to stimulate the same GLP-1 hormone that Ozempic-class drugs mimic, which is exactly why it is being marketed as "natural GLP-1 support." The honest verdict: promising mechanism, one small human study, and consumer doses that sit far below what that study used. Worth watching, reasonable to try, not yet established.
The mechanism is the compelling part. Akkermansia lives in your gut mucus layer and secretes a protein (called P9) that prompts your intestinal cells to release GLP-1 - the incretin hormone that controls appetite and blood sugar (Yoon 2021). It also strengthens the gut barrier and feeds beneficial short-chain-fatty-acid producers. That is a real, characterized pathway, and two 2026 human papers have begun connecting pasteurized Akkermansia to insulin sensitivity, body composition, and GLP-1 signaling (Suenaert 2026; Dinkov 2026).
Here is the catch that the marketing skips, and it is a big one. The one good human RCT (Depommier 2019, 32 completers) found that the pasteurized (heat-killed) form improved insulin sensitivity by about 30%, while the live form - which is what almost every consumer product sells - did not produce statistically significant metabolic benefits. On top of that, consumer products deliver around 100 million cells (AFU) per capsule, roughly 100 times less than the 10 billion pasteurized cells used in that trial. A 2024 trial also found the benefit depends on how much Akkermansia you already have in your gut. So the evidence is real but thin, and it does not cleanly match what is on the shelf.
For products, the market is effectively one brand. Pendulum was first to bring a live Akkermansia strain to market, holds the patent and the only brand-run clinical data, and prices accordingly (roughly $50-80 a month depending on the formula). Codeage is the one credible cheaper alternative at a matching cell count. Beyond those two, you will see obscure brands advertising "30 billion" live Akkermansia - counts that are implausible for a strict anaerobe and that we found no independent verification for. If you want to try this, the sensible path is Pendulum's clinically studied strain or the cheaper Codeage, taken as a several-month experiment rather than a proven therapy.
Does It Work? The Evidence
How A-F grades workAkkermansia muciniphila earns a Mixed Evidence rating: the research is suggestive but not settled. Its best-supported uses so far are improves insulin sensitivity and metabolic markers and stimulates GLP-1 secretion (the 'natural GLP-1' mechanism) (grade B), but the evidence across claims is mixed - each is graded on its own below.
Improves insulin sensitivity and metabolic markers
Depommier et al. 2019 (Nature Medicine): 3-month RCT, pasteurized A. muciniphila improved insulin sensitivity ~30% and lowered insulinemia/total cholesterol vs placebo
Stimulates GLP-1 secretion (the 'natural GLP-1' mechanism)
Yoon et al. 2021 (Nature Microbiology): identified the P9 protein that induces GLP-1 release; Dinkov 2026 and Suenaert 2026 extend the GLP-1 link into early human work
Strengthens the gut barrier
Cani et al. 2022 (Nat Rev Gastroenterol Hepatol) review: Akkermansia degrades mucin and reinforces gut-barrier integrity - well characterized mechanistically
Supports weight and body composition
Depommier 2019 found modest fat-mass reduction; Suenaert 2026 reported body-composition effects with pasteurized strain - small studies, not yet confirmed at scale
The live form (sold in most products) delivers the trial's metabolic benefit
Depommier 2019: the pasteurized form improved metabolic markers while the live form did not reach significance; most consumer products sell the live form
| Grade | Claimed Benefit | Key Studies | Our Verdict |
|---|---|---|---|
| B | Improves insulin sensitivity and metabolic markers | Depommier et al. 2019 (Nature Medicine): 3-month RCT, pasteurized A. muciniphila improved insulin sensitivity ~30% and lowered insulinemia/total cholesterol vs placebo | Early Signal |
| B | Stimulates GLP-1 secretion (the 'natural GLP-1' mechanism) | Yoon et al. 2021 (Nature Microbiology): identified the P9 protein that induces GLP-1 release; Dinkov 2026 and Suenaert 2026 extend the GLP-1 link into early human work | Early Signal |
| B | Strengthens the gut barrier | Cani et al. 2022 (Nat Rev Gastroenterol Hepatol) review: Akkermansia degrades mucin and reinforces gut-barrier integrity - well characterized mechanistically | Early Signal |
| C | Supports weight and body composition | Depommier 2019 found modest fat-mass reduction; Suenaert 2026 reported body-composition effects with pasteurized strain - small studies, not yet confirmed at scale | Early Signal |
| D | The live form (sold in most products) delivers the trial's metabolic benefit | Depommier 2019: the pasteurized form improved metabolic markers while the live form did not reach significance; most consumer products sell the live form | Conflicted |
How to Choose: Forms, Doses & What Matters
Clinical dose: The human trial used ~10 billion pasteurized cells/day; consumer live products deliver ~100 million AFU (roughly 100x less)
Best forms: delayed-release capsule (survives stomach acid), the patented, clinically studied strain, refrigerated to preserve viability
Take one capsule a day, typically with food, and keep it refrigerated - Akkermansia is a fragile anaerobe and viability drops with heat and time. Delayed-release capsules matter here because the bacterium needs to survive stomach acid to reach the colon, so favor products that use them. Give it two to three months; any metabolic effect builds gradually as the organism colonizes, and colonization itself varies from person to person. Do not expect the appetite suppression of a GLP-1 drug.
Who Should Take Akkermansia muciniphila?
This is worth considering if you are focused on metabolic health - insulin sensitivity, blood-sugar control, or body composition - and you like being early to a promising but unproven idea. It has a logical appeal for people on, tapering off, or trying to avoid GLP-1 medications, since it works on the same hormone pathway, though no trial has tested it as a companion to those drugs. Treat it as a several-month experiment and track how you feel and any relevant labs.
Who Should Avoid It?
Not for everyone
Side Effects & Safety
Product Scores
5 products scored on dosing accuracy, third-party testing, cost per effective dose, and label transparency.
The Scorecard: 5 Products Compared
Akkermansia Probiotic
Pendulum
$54.00 ÷ 30 days at 0.1billion AFU/day (1 serving × 0.1billion AFU)
The reference product for the category - the strain the science is actually about. In our view the premium is defensible for a fragile anaerobe where strain identity and viability are hard to verify in generics.
Prices checked 2026-07-05. Cost shown is per clinically effective daily dose, not per pill.
Akkermansia Muciniphila Probiotic
Codeage
$34.99 ÷ 90 days at 0.1billion AFU/day (1 serving × 0.1billion AFU)
The credible way to try Akkermansia cheaply. You give up the patented, clinically studied strain, but the cell count matches and the price is far lower.
Prices checked 2026-07-05. Cost shown is per clinically effective daily dose, not per pill.
Metabolic Daily Probiotic
Pendulum
$49.00 ÷ 30 days at 24billion AFU/day (1 serving × 24billion AFU)
A broader metabolic blend if you want butyrate producers alongside Akkermansia, though the per-strain Akkermansia dose is not spelled out.
Prices checked 2026-07-05. Cost shown is per clinically effective daily dose, not per pill.
GLP-1 Probiotic
Pendulum
$79.00 ÷ 30 days at 0.5billion AFU/day (1 serving × 0.5billion AFU)
The SKU built explicitly around the GLP-1 story. The strains are legitimate, but in our view the name promises more than the human evidence yet delivers, and it carries the highest price in the line.
Prices checked 2026-07-05. Cost shown is per clinically effective daily dose, not per pill.
Akkermansia Muciniphila Gut Health
Vitamatic
$24.99 ÷ 60 days at 0.1billion AFU/day (1 serving × 0.1billion AFU)
Cheap, but we found no independent verification of the viable Akkermansia count, and the brand's higher-count sibling products claim numbers that are hard to reconcile with how a strict anaerobe is manufactured. We would not rely on it to deliver a known dose.
Prices checked 2026-07-05. Cost shown is per clinically effective daily dose, not per pill.
Full Comparison
| Category | Akkermansia Probiotic Pendulum | Akkermansia Muciniphila Probiotic Codeage | Metabolic Daily Probiotic Pendulum | GLP-1 Probiotic Pendulum | Akkermansia Muciniphila Gut Health Vitamatic |
|---|---|---|---|---|---|
| Brand Score | 72/100Winner | 71/100 | 67/100 | 65/100 | 51/100 |
| Dosing & Form | 19/25Winner | 17/25 | 18/25 | 18/25 | 12/25 |
| Purity | 21/25Winner | 14/25 | 20/25 | 20/25 | 9/25 |
| Value | 12/25 | 21/25Winner | 12/25 | 9/25 | 18/25 |
| Transparency | 20/25Winner | 19/25 | 17/25 | 18/25 | 12/25 |
| Cost/Day | $1.80 | $0.39Winner | $1.63 | $2.63 | $0.42 |
| Dose/Serving | 0.1billion AFU | 0.1billion AFU | 24billion AFU | 0.5billion AFU | 0.1billion AFU |
| Form | Delayed-release capsule (100M AFU + inulin) | Capsule (100M AFU + chicory inulin) | Capsule (4-strain blend + inulin) | Delayed-release capsule (3-strain blend + inulin) | Delayed-release capsule (+ inulin) |
| Third-Party Tested | ✓ Yes | No | ✓ Yes | ✓ Yes | No |
| Proprietary Blend | No | No | No | No | No |
Frequently Asked Questions
Is Akkermansia really a 'natural Ozempic'?
That framing overstates it. Akkermansia does stimulate GLP-1 - the same hormone GLP-1 medications mimic - through a protein it secretes called P9, so the mechanism is real and shared. But the effect in humans is small and preliminary, nothing like the appetite suppression and weight loss of semaglutide or tirzepatide. It is better understood as a metabolic-health supplement with a GLP-1-linked mechanism than as a natural substitute for the drugs.
Does Akkermansia actually work?
The honest answer is 'maybe, early days.' One proof-of-concept human RCT found improved insulin sensitivity and modest metabolic benefits, but with the pasteurized (heat-killed) form, while most products sell the live form. Consumer doses are also about 100x lower than the study used. The mechanism is genuinely interesting and newer human work is building the case, but this is not yet an established therapy - treat it as a promising experiment.
Is Pendulum worth the premium over cheaper Akkermansia?
Pendulum was first to market a live Akkermansia strain, holds the patent, and is the only brand with its own published human data - which for a fragile, hard-to-manufacture anaerobe is a real quality signal you cannot easily verify in a generic. Codeage offers a matching cell count at roughly a fifth of the cost and is the credible value alternative. In our view Pendulum earns the Top Pick for the strain and clinical pedigree, but Codeage is a reasonable way to try the idea for less.
Why do some Akkermansia products claim billions of cells and others only 100 million?
Akkermansia is a strict anaerobe that is difficult to keep alive at high counts in a shelf-stable capsule. The clinically studied products and Pendulum use around 100 million AFU (active fluorescent units). Products advertising '30 billion' or '3 billion' live Akkermansia make counts that are hard to reconcile with the manufacturing reality, and we found no independent verification that they deliver that many viable organisms - a claim to treat with skepticism, not as a better dose.
Do I need to refrigerate Akkermansia?
For live products, yes - refrigeration helps preserve viability of this fragile bacterium. Pendulum recommends it. Heat and time degrade live counts, so a product left warm may deliver far fewer viable organisms than the label states by the time you take it.
Can I take Akkermansia with a GLP-1 medication?
There is no established interaction, and the mechanisms overlap rather than conflict, but no trial has tested Akkermansia specifically alongside semaglutide or tirzepatide. As with any supplement added while on a prescribed medication, run it past the clinician managing your GLP-1 therapy, especially if you also take other glucose-lowering drugs.
Related Reading
Sources
- Depommier C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096-1103.
- Yoon HS, et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nat Microbiol. 2021;6(5):563-573.
- Cani PD, et al. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol. 2022;19(10):625-637.
- Suenaert P, et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 in adults. Gut Microbes. 2026.
- Dinkov B, et al. Akkermansia muciniphila and GLP-1-Based Therapies: Bidirectional Interactions and Implications for Metabolic Health. Biomedicines. 2026.
Scores and tiers are our independent opinion, formed by applying a published rubric to label data, third-party certifications, and the research record. They are not statements of objective fact about a product and not a lab test. Where we report a brand-specific fact, it comes from a cited source or a public certification; where verification is missing, we say so rather than assume a result.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any supplement regimen.